Wigow is preparing to launch a weight-loss product for dogs described as "Mounjaro for dogs" [1].

The move signals a growing trend of adapting human pharmaceutical breakthroughs for veterinary use. As pet owners increasingly seek medical interventions for animal obesity, companies are targeting high-revenue opportunities in the specialized pet health market.

Wigow has set a target revenue of R$1 billion [1] for the new product. The company is positioning the treatment to address canine weight management, mirroring the mechanisms of weight-loss drugs used by humans.

The development comes as the global pet care industry shifts toward more advanced medical treatments. By applying the concepts of GLP-1 receptor agonists, the class of drugs that includes Mounjaro, to dogs, Wigow seeks to capture a significant share of the animal health sector [1].

While the company has outlined its financial goals, specific details regarding the clinical trial phases or the exact date of the market release have not been detailed in the announcement [1]. The focus remains on the projected financial impact and the product's conceptual alignment with human weight-loss medications.

“Wigow is preparing to launch a weight-loss product for dogs”

The effort to create a canine version of GLP-1 medications reflects the 'humanization' of pet care, where veterinary medicine adopts human pharmaceutical trends. If successful, the R$1 billion revenue target suggests a massive untapped market for medical weight management in pets, potentially shifting the industry away from dietary supplements toward prescription-grade pharmacological interventions.